Francisco Gerardo Padilla Padilla
Welcome,         Profile    Billing    Logout  
 0 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Padilla, Francisco G Padilla
NCT04882293: Efficacy and Safety of the Fixed-dose Combination Atorvastatin/Fenofibrate vs Atorvastatin in Patients With T2D and DLP.

Recruiting
3
78
RoW
Atorvastatin 20 mg / Fenofibrate 160 mg in fixed dose, ATV / FENO, Atorvastatin (Lipitor ®), ATV (Lipitor ®)
Laboratorios Silanes S.A. de C.V.
Dyslipidemia Associated With Type II Diabetes Mellitus
05/22
05/22
NCT04927299: Efficacy and Safety of Losartan/Chlorthalidone vs Losartan/Hydrochlorothiazide in Essential Arterial Hypertension

Completed
3
163
RoW
Losartan/Chlorthalidone in fixed dose, LOS/CHLORTHA, Losartan + hydrochlorothiazide in fixed dose, LOS/HYDROCHLO
Laboratorios Silanes S.A. de C.V.
Essential Arterial Hypertension
08/23
09/23
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
NCT05565742: A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]

Completed
2
320
Europe, Japan, US, RoW
LY3819469, Placebo
Eli Lilly and Company
Lipoprotein Disorder
10/23
10/24
LACROSS, NCT04456842: Cardiovascular Registry of Atrial Fibrillation

Completed
N/A
2016
RoW
Patient Registry Data
Brazilian Clinical Research Institute
Atrial Fibrillation, Atrial Flutter
09/24
09/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Padilla, Francisco G Padilla
NCT04882293: Efficacy and Safety of the Fixed-dose Combination Atorvastatin/Fenofibrate vs Atorvastatin in Patients With T2D and DLP.

Recruiting
3
78
RoW
Atorvastatin 20 mg / Fenofibrate 160 mg in fixed dose, ATV / FENO, Atorvastatin (Lipitor ®), ATV (Lipitor ®)
Laboratorios Silanes S.A. de C.V.
Dyslipidemia Associated With Type II Diabetes Mellitus
05/22
05/22
NCT04927299: Efficacy and Safety of Losartan/Chlorthalidone vs Losartan/Hydrochlorothiazide in Essential Arterial Hypertension

Completed
3
163
RoW
Losartan/Chlorthalidone in fixed dose, LOS/CHLORTHA, Losartan + hydrochlorothiazide in fixed dose, LOS/HYDROCHLO
Laboratorios Silanes S.A. de C.V.
Essential Arterial Hypertension
08/23
09/23
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
NCT05565742: A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]

Completed
2
320
Europe, Japan, US, RoW
LY3819469, Placebo
Eli Lilly and Company
Lipoprotein Disorder
10/23
10/24
LACROSS, NCT04456842: Cardiovascular Registry of Atrial Fibrillation

Completed
N/A
2016
RoW
Patient Registry Data
Brazilian Clinical Research Institute
Atrial Fibrillation, Atrial Flutter
09/24
09/24

Download Options